课题基金 / 基金详情

Basic Analysis of Immuno-gene Therapy for Melanoma Using Functional Characteristic of CD82

Basic Analysis of Immuno-gene Therapy for Melanoma Using Functional Characteristic of CD82
利用CD82功能特性进行黑色素瘤免疫基因治疗的基础分析
批准号:
09670905
负责人:
SHIBAGAKI Naotaka
金额:
$1.79万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1998

项目摘要

项目成果

SHIBAGAKI Naotaka的其他基金

相似基金

相关文献

中文摘要
翻译
为了确定在T细胞活化的早期阶段起作用的T细胞共刺激分子,我们建立了抑制或增强组织细胞白血病细胞系U937的T细胞活化的单克隆抗体(mAb)。通过表达克隆,鉴定了识别T细胞和U937的mAb之一53 H5与CD 82结合。CD 82的功能分析表明:1)CD 82需要同时存在于T细胞和U937上才能完全激活T细胞; 2)通过刺激如CD 3连接或PMA处理,CD 82在T细胞和U937上的表达上调; 3)CD 82的过表达增强T细胞与U937之间的同型和异型细胞粘附; 4)CD 82信号共刺激T细胞,并且该信号与CD 28介导的T细胞共刺激信号协同作用; 5)在使用U937作为刺激细胞的混合白细胞反应(MLR)中,U937上的CD 82过表达与U937细胞的较高同种异体性相关; 6)黑素瘤细胞上的CD 82过表达增强黑素瘤细胞与T细胞之间的异型细胞粘附。这些结果表明,CD 82在T细胞和抗原呈递细胞或靶细胞上均表达,不仅作为T细胞中的共刺激分子,而且作为细胞粘附分子发挥重要作用。
英文摘要
To define T-cell costimulatory molecules that work in the early phase of T-cell activation, we established monoclonal antibodies (mAbs) that inhibit or enhance T-cell activation by histiocytic leukemia cell line U937. One of the mAbs, 53H5, that recognized both T cells and U937 was identified to bind to CD82 by expression cloning. Functional analyses of CD82 revealed the following : 1) CD82 needs to exist on both T cells and U937 for the full activation of T cells ; 2) CD82 expression is up-regulated on both T cells and U937 by stimulation such as CD3 ligation or PMA treatment ; 3) overexpression of CD82 enhances both homotypic and heterotypic cell adhesion between T cells and U937 ; 4) CD82 signal costimulates T cells and the signal works synergistically with the CD28-mediated T-cell costimulation signal ; 5) in mixed leukocyte reaction (MLR) using U937 as stimulator cells, CD82 overexpression on U937 correlates with the higher allogeneicity of U937 cells ; 6) overexpression of CD82 on melanoma cells enhances heterotypic cell adhesion between melanoma cells and T cells. These results indicate that CD82, expressed on both T cells and antigen presenting cells or target cells, plays an important role not only as a costimulatory molecules in T cells, but also as a cell adhesion molecules.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Naotaka Shibagaki, et al.: "Functional analysis of CD82 in the early phase of T cell activation:roles in cell adhesion and signal transduction." European Journal of Immunology.28. 1125-1133 (1998)
Naotaka Shibagaki 等人:“T 细胞激活早期阶段 CD82 的功能分析:在细胞粘附和信号转导中的作用。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Analyses for the establishment of the effective immunotherapy to melanoma-bearing hosts
  • 批准号:
    23591613
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $3.49万
  • 财政年份:
    2011
  • 负责人:
    SHIBAGAKI Naotaka
  • 依托单位:
Novel therapeutic approach to skin diseases with protein-transduction technology
  • 批准号:
    20591316
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $3.08万
  • 财政年份:
    2008
  • 负责人:
    SHIBAGAKI Naotaka
  • 依托单位:
Analyses for the enhancing methods of tumor vaccination therapy in cancer-bearing hosts
  • 批准号:
    18591241
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $2.49万
  • 财政年份:
    2006
  • 负责人:
    SHIBAGAKI Naotaka
  • 依托单位:
Analysis of Antitumor Immunity Using Dendritic Cells Treated with Various Protein-transduction Domain (PTD)-containing Protein Antigen
  • 批准号:
    15390339
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 资助金额:
    $9.6万
  • 财政年份:
    2003
  • 负责人:
    SHIBAGAKI Naotaka
  • 依托单位:
海外基金